Alkermes plc., formerly dba Alkermes, Inc., merged with Elan Drug Technologies in September of 2011. The company is an integrated biotechnology company in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases. In March 2002, the merger of Alkermes, Inc. with Reliant Pharmaceuticals, LLC ("Reliant") was announced - Reliant indicated as being a privately-held company owned primarily by the Pritzker family business interests. Previously Massachusetts based, Alekrmes has long since outgrown the SBIR program and is now located in Ireland. The Company develops, manufactures and commercializes VIVITROL for alcohol dependence and manufacture RISPERDAL CONSTA for schizophrenia and bipolar I disorder. Its pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system (CNS), disorders, reward disorders, addiction, diabetes and autoimmune disorders. The Company has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.
